Clinical Perspectives of Single-Cell RNA Sequencing

Nayoung Kim 1,2,†, Hye Hyeon Eum 1,2,† and Hae-Ock Lee 1,2,*

1 Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea; wwkdl0324@gmail.com (N.K.); hheum1107@gmail.com (H.H.E.)
2 Department of Biomedicine and Health Sciences, Graduate School, The Catholic University of Korea, Seoul 06591, Korea
* Correspondence: haeocklee@catholic.ac.kr; Tel.: +82-2-2258-8155
† Equal contribution.

Abstract: The ability of single-cell genomics to resolve cellular heterogeneity is highly appreciated in cancer and is being exploited for precision medicine. In the recent decade, we have witnessed the incorporation of cancer genomics into the clinical decision-making process for molecular-targeted therapies. Compared with conventional genomics, which primarily focuses on the specific and sensitive detection of the molecular targets, single-cell genomics addresses intratumoral heterogeneity and the microenvironmental components impacting the treatment response and resistance. As an exploratory tool, single-cell genomics provides an unprecedented opportunity to improve the diagnosis, monitoring, and treatment of cancer. The results obtained upon employing bulk cancer genomics indicate that single-cell genomics is at an early stage with respect to exploration of clinical relevance and requires further innovations to become a widely utilized technology in the clinic.

Keywords: single-cell genomics; single-cell RNA sequencing; treatment response; patient stratification; clinical decision

1. Introduction

Cells are the basic units of all living organisms. Single-cell genomics has ushered in a new era in biology by employing genomics to define cellular identity and states. Genomic data of individual cells provide the status of thousands of genes or regulatory elements simultaneously. For instance, data pertaining to the transcriptome and the epigenome (chromatin openness) can be obtained through single-cell RNA sequencing (scRNA-seq) and single-cell ATAC-seq (assay for transposase-accessible chromatin with sequencing), respectively. As cellular identity and function are closely linked to the spatial and temporal positions of cells, genomic data complement the traditional cell type definition that takes into consideration of the anatomical, morphological, and developmental traits. Massively parallel genomic analyses recapitulate dynamic cellular states and therefore, single-cell genomics provides high-resolution criteria for determining the cellular identities in health and disease conditions.

Cancer is defined as an abnormal growth of cells characterized by uncontrolled division and the ability of these cells to invade and destroy normal tissue architectures. From a genomic perspective, cancer is a disease that arises as a result of genomic instability, a phenomenon that disrupts the normal genomic program in healthy cells within the tissue context. Indeed, single-cell transcriptome analysis has demonstrated the separation of cancer cells from normal counterpart cells with the cancer cells positioned in distinct clusters in each patient while non-malignant cells show multi-patient clustering, suggesting a gross deviation from the normal genomic programs [1,2] (Figure 1A–C). The transcriptional clusters may—in part—represent specific genetic alterations or transcriptional modules associated with tumor progression, metastasis, and response, and resistance to a specific treatment [1,3–5]. In addition to the genomic characterization of tumor cells, single-cell
genomics allows for the cellular dissection and the characterization of the tumor microenvironment, which influences tumor cell behavior and the effect of anti-cancer therapies directed at stromal and immune cells [2] (Figure 1D).

In clinical practice, the benefits associated with the implementation of single-cell resolution cancer genomics are uncertain. Here, we will review the clinical implementation of conventional cancer genomics and examine clinical cases and areas that are addressed by single-cell genomics, and then discuss whether and how this technology will promote the development of better strategies to diagnose, monitor, and treat cancer.

2. Brief Overview of Cancer Genomics in Precision Oncology

There were quite some hurdles to utilizing cancer genome data to make clinical decisions regarding the treatment choices. Molecular target discoveries that aid platform development for clinical implementation would enable us to obtain a better understanding whether and how the single-cell genomics data can be incorporated into the clinical decision-making process (Table 1).
Table 1. Cancer genomics implemented in the clinical decision process.

| Genomic Features Purpose | Representative Test Target Tumor | Test Platform Coverage | Diagnostic Use |
|--------------------------|----------------------------------|------------------------|----------------|
| Genomic DNA (+RNA in Oncomine Dx): DNA point mutations, gene amplification, translocation, TMB, HRD Molecular targeted therapy Response prediction | FoundationOne CDx Solid tumors | NGS panel | FDA approved |
| | Oncomine Dx NSCLC | 324 genes | 16 CDx indications |
| | MSK-IMPACT Solid tumors | 23 genes from DNA and fusions in ROS1 and RET from RNA | FDA approved |
| | | NGS panel | 4 genes CDx in NSCLC |
| | | 468 genes Microarray | FDA approved |
| | | 70 genes NanoString nCounter | No indication |
| RNA Gene expression Prognostic Predictive | Mammaprint Breast cancer | 58 genes RT-PCR | FDA approved |
| | Prosigna (Pam50) Breast cancer | RT-PCR | NCCN guidelines |
| | Oncotype Dx Breast cancer | 21 genes RT-PCR | NCCN guidelines |
| | Breast Cancer Index Breast cancer | 7 genes RT-PCR | NCCN guidelines |
| | EndoPredict test Breast cancer | 12 genes RT-PCR | NCCN guidelines |

TMB, tumor mutational burden; HRD, homologous repair deficiency; CDx, companion diagnostics; NCCN, national comprehensive cancer network.

2.1. Molecular Target Discoveries and NGS Panel Sequencing

Imatinib (Gleevec)—targeting BCR-ABL in chronic myeloid leukemia—is one of the most successful molecular-targeted therapies for genetic aberrations in cancer [7]. It took 30 years from the discovery of the truncated chromosome 22—Philadelphia chromosome—to the identification of the BCR-ABL gene fusion and another 10 years for the clinical trial on the tyrosine kinase inhibitor imatinib [8]. Next generation sequencing (NGS) enabled the analysis of the entire human genome and influenced the launching of cancer genome projects such as The Cancer Genome Atlas (TCGA)—in 2005—and the International Cancer Genome Consortium (ICGC) in 2008 [9], which led the community efforts to obtain a comprehensive understanding of the genomic alterations underlying all major cancers. Starting from the first markup study on the glioblastoma genome [10], TCGA has provided insights into the genomic landscapes of over 33 cancer types [11] and ICGC has provided insights into the genomic landscapes of over 50 cancer types in less than 15 years. It suffices to say that now we have a genomic draft for major cancer types. The draft, which focused on the protein-coding regions and expanded to the non-coding areas of the human genome, remarkably accelerated the discovery of genetic aberrations in cancer.

While whole genome, exome, or transcriptome sequencing provide more extensive information about genomic alterations in cancer, currently only gene panel sequencing is employed in clinical settings [11,12]. Oncomine Dx Target Test, FoundationOne CDx, and MSK-IMPACT are the representative US FDA-approved NGS panel platforms covering different ranges of point mutations, gene amplifications, translocations, and complex genomic features such as tumor mutational burden (TMB) or homologous recombination deficiency (HRD) that guide molecular-targeted therapies in lung cancer or multiple cancer types [13]. The tangent from the emergence of cancer genomics to the clinical implementation of panel sequencing indicates the requirement of two parallel areas of research, i.e., one linking genomic alterations to treatment response [14,15] and the other involving the formulation of efficient strategies for detecting clinically significant alterations [16].

Association of genomic alterations with treatment response in cancer is categorized in multiple tiers [14], with druggable mutations used in companion diagnostics (CDx) at the highest level, cancer mutations with evidence of clinical significance at the second level, and cancer mutations with potential clinical significance at the third level. For example, FoundationOne CDx in the current form detects genetic aberrations in 324 genes and three genomic features, i.e., microsatellite instability (MSI), TMB, and HRD status [17]. Among these, CDx indications include non-small cell lung cancer (NSCLC) with $EGFR$ exon 19 deletions and $EGFR$ exon 21 L858R alterations (for afatinib, gefitinib, or erlotinib); $EGFR$ exon 20 T790M for osimertinib; ALK rearrangements (for alectinib, crizotinib, or ceritinib);
and BRAF V600E (for dabrafenib in combination with trametinib). Additional indications include melanoma with BRAF 600E and V600K alterations, breast cancer with ERBB2 (HER2) amplification, colorectal cancer with KRAS wild-type (absence of mutations in codons 12 and 13, or exons two, three, and four) and NRAS wild-type, and ovarian cancer with BRCA1/2 alterations. TMB (>10 mutations per megabase) can be used as a marker for the outcomes of pembrolizumab immune checkpoint therapy in solid tumors. CDx level genomic alterations are relatively few among all the detected genetic aberrations in a given assay, but are slowly expanding with the emergence of stronger evidence of clinical significance, as seen in the case of NTRK gene fusion [18].

2.2. Gene-Expression-Based Patient Stratification

Another example of the involvement of genomic datasets in the clinical decision-making process is prognostic testing. Oncotype Dx and Mammaprint are representative assays used in the recurrence risk assessment of early-stage breast cancer [19]. Oncotype Dx provides a recurrence score obtained from RT-PCR-based expression data of 21 genes, and Mammaprint reveals the risk of distant recurrence 10 years after diagnosis based on a microarray-based gene expression score of 70 genes [20]. These assays are recommended in clinical guidelines, such as the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO), as prognostic and therapy-predictive (Oncotype Dx only) assays complementing other clinical data. In multiple myeloma, MyPRS [21] and SKY-92 [22] provide microarray-based gene expression signature scores for risk stratification. However, these remain investigational, and their clinical implementation requires further validation. Though development of gene-expression-based complementary diagnostics has relied on the accumulation of microarray data with clinical annotations over many years, RNA sequencing has now emerged as the preferred method for high-throughput gene expression analysis. By comparison, RT-PCR is mostly employed as an assay for evaluating the expression of a small number of genes and is comparable to the panel sequencing strategy that is used for the efficient detection of selective DNA aberrations.

3. Tumor Heterogeneity Is Responsible for Treatment Resistance in Precision Oncology

Heterogeneous tumor cell populations—with variations in the proliferative capacity, tumor antigen expression, immune cell activation, or other characteristics affecting tumor growth and the response to anti-cancer drugs—are present within a single tumor. Intratumoral heterogeneity, investigated based on protein marker expression in tissues or isolated tumor populations—before the genomics era—has long been suspected to be responsible for the development of treatment resistance. Genomic analyses nowadays allow the systemic assessment of tumor cell properties, and multi-regional or single-cell genomics elaborate on the degree of intratumoral heterogeneity and its effects.

3.1. Tumor Heterogeneity Fine-Tuning Molecular-Targeted Therapies

As conditions associated with genomic instability, tumors evolve to generate multiple clones with discrete genomic profiles [23]. Multi-regional and longitudinal genomic studies on cancer have demonstrated the presence of genetic clones with different mutations, copy number alterations, and multiple epigenome and transcriptome profiles in a single patient [24,25]. Intratumoral heterogeneity poses a serious challenge in genome-based molecular-targeted therapy, as pre-existing non-target populations persist and result in disease relapse. To avoid the incomplete targeting of subset populations, treatments directed at truncal mutations shared by all tumor cells or drug combinations targeting all subclones can be adopted [26]. This approach involves the inclusive sampling of tumor tissues representing the whole tumor, which is difficult to achieve with biopsy specimens. Furthermore, tumor evolution has a much broader scope than that of pre-existing non-target clones. In a recent series of publications, the TRAcking non-small cell lung Cancer Evolution through therapy (TRACERx) consortium demonstrated spatial tumor heterogeneity in lung
cancer arising from genetic evolution, transcriptomic diversification, and interplay with the immune microenvironment [27–33].

While multi-regional or multi-temporal sequencing is mainly used for the phylogenetic reconstruction of tumor evolution, tumor subclonal heterogeneity can be estimated within a single tumor sample based on the variant allele frequency of single nucleotide variants (SNVs) and large copy number alterations (CNAs) [34]. Tumor subclonal heterogeneity, which can be estimated from bulk sequencing data, is associated with more aggressive tumor growth, metastasis, and treatment resistance [25,35,36]. DNA sequencing at the single cell or the single nucleus levels also enables the reconstruction of subclonal structures in cancer, with both advantages and disadvantages compared to bulk analysis [37]. Single-cell or nuclear CNA overcomes the issues associated with ambiguities in tumor purity or ploidy as well as insensitivities to rare clones, if successfully captured, in bulk samples. However, the small number of assayed cells may not represent the diverse subclonal populations in the whole tumor. Uneven and low genome coverage due to the limited starting material and the extensive amplification also introduce errors in the estimation of DNA in single cells [37]. While ongoing technical advancement continues to increase the resolution and the scope of single-cell/nucleus-level DNA analysis in the reconstruction of tumor evolutionary paths [38], these limitations yield a bias and an underestimation of subclonal heterogeneity at single-cell resolution. Thus, in the estimation of genetic heterogeneity, bulk-level analyses are likely to provide reliable information regarding the complex subclonal structures that may affect the efficacy of molecular-targeted therapies.

Detection of genetic aberrations in circulating tumor cells (CTCs) or in tumor cells of minimal/measurable residual disease (MRD) could provide an early window for molecular target selection ahead of metastasis or relapse [39]. The frequencies of CTCs in solid tumors or in the residual tumor load during remission are extremely low, and bulk genomic analysis often fails to capture the tumor cell signals. Enrichment of EPCAM+CD45-cells and subsequent single-cell DNA sequencing, rather than simple enumeration, could provide information regarding the genetic characteristics of CTCs with a high metastatic potential in solid tumors. In acute myeloid leukemia (AML), tumor clones can be detected in 80% of patients during remission using single-cell sequencing [40]. While single-cell level DNA sequencing allows for more comprehensive genetic profiling of specific tumor clones, capturing rare tumor clones requires large numbers of single-cell sampling. Thus, the development of an efficient target cell capture platform—in terms of throughput and cost—is required for the practical use of single-cell genomics for monitoring the CTCs or residual tumor load.

3.2. Gene Expression Heterogeneity Associated with Prognosis, Treatment, and Patient Stratification

Unlike the assessment of genotype diversity at the DNA level, intratumoral heterogeneity assessment based on gene expression data requires analyses at a single-cell resolution due to its quantitative nature. At the tissue level, gene expression data have been used for tumor subtype assessment and patient stratification in multiple cancer types [41–43]. As scRNA-seq data dissect gene expression heterogeneity at the cellular level, the tumor subtype classification gets updated to distinguish tumor signatures and stromal characteristics surrounding the tumor [44] (Figure 2 and Table 2).
Table 2. Single-cell studies dissecting tumor signatures and specific microenvironment.

| Tumor Type       | Technology | Main Findings                                                                                                                                                                                                 | References |
|------------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| NSCLC            | scRNA-seq  | A cancer cell subtype deviating from the normal differentiation trajectory is associated with poor survival in lung adenocarcinoma. Metastatic lung cancer reveals pro-tumoral and immunosuppressive microenvironment along with expansion of monocyte-derived macrophages and dendritic cells, and exhausted T-cells. Heterogenous epithelial cell types spread along cancer developmental trajectories. | [45]       |
| NSCLC            | scRNA-seq  | Rare cell types such as follicular dendritic cells and T helper 17 cells are identified in the advanced NSCLC. cDC2 displayed Langerin (CD207) is associated with clinical outcomes in lung adenocarcinoma. | [46]       |
| Breast cancer    | snDNA-seq  | Heterogenous epithelial cell types spread along cancer developmental trajectories. Rare cell types such as follicular dendritic cells and T helper 17 cells are identified in the advanced NSCLC. cDC2 displayed Langerin (CD207) is associated with clinical outcomes in lung adenocarcinoma. | [45]       |
| Breast cancer    | scDNA-seq; scRNA-seq | Subclones associated with chemoresistance are pre-existing in the tumor. The classification according to consensus molecular subtypes reflects both the tumor and its associated microenvironment. | [46]       |
| Colon cancer     | scRNA-seq  | The classification according to consensus molecular subtypes reflects both the tumor and its associated microenvironment. Heterogeneous copy number alterations explain intra- and inter-patient variation of malignant cells. | [49]       |
| Ovarian cancer   | scRNA-seq  | Diverse subsets of cancer-associated fibroblasts and macrophages show inter-patient variability. Aneuploid rearrangements burst early in tumor evolution. | [50]       |
| Glioblastoma     | scRNA-seq  | Four cellular states of malignant cells are identified in glioblastoma, which are influenced by their associated microenvironment and exhibit plasticity. Glioblastoma subtypes which have variable expression in diverse transcriptional programs and prognostic implications are identified. Head and neck squamous cell carcinoma (HNSCC) subtype vary in cell cycle, stress, hypoxia, and epithelial differentiation. | [51]       |
| Glioblastoma     | scRNA-seq  | Glioblastoma subtypes which have variable expression in diverse transcriptional programs and prognostic implications are identified. Head and neck squamous cell carcinoma (HNSCC) subtype vary in cell cycle, stress, hypoxia, and epithelial differentiation. | [1]        |
| Head and neck cancer | scRNA-seq | A partial epithelial-to-mesenchymal transition (p-EMT), one of HNSCC subtypes, is a predictor of metastasis and progression. Diverse transcriptional heterogeneity across malignant cells within a tumor is related to the cell cycle, spatial context, and a drug-resistance program. | [52]       |
| Melanoma         | scRNA-seq  | Diverse transcriptional heterogeneity across malignant cells within a tumor is related to the cell cycle, spatial context, and a drug-resistance program. Malignant cells with elevated levels of AXL and MITF coexist in melanoma. | [2]        |

First, single tumor sites were frequently populated by multiple tumor subtype cells, implying compound tumor cell behavior. In glioblastoma, individual tumor cells in a single patient can be classified into diverse subtypes, such as proneural, neural, classical, and/or mesenchymal types, as well as hybrid cell types [1]. This multiple subtype composition and hybrid status suggested a variation in the susceptibility of tumor cells to conventional and molecular-targeted therapies and underscored their plasticity as well. In addition, in breast cancer, the presence of the rare triple-negative breast cancer (TNBC) subtype cells in estrogen receptor (ER)-positive tumors indicated the existence of pre-existing tumor clones with intrinsic resistance to hormone therapy [53]. Second, tissue-level mesenchymal subtypes associated with poor patient survival reflect the overabundance of cancer-associated fibroblasts (CAFs) in colorectal and ovarian cancers [49,50,54]. In these tumors, conventional gene expression patterns signifying an epithelial–mesenchymal transition (EMT) were found to originate from CAFs rather than from tumor cells. In head and neck squamous cell carcinoma, partial EMT programs that are different from the conventional EMT signatures have been identified [52]. Identification of transcriptional programs governing the epithelial tumor cell-specific EMT could help redefine the regulatory pathways of metastasis and may reveal new strategies to control the metastatic phenotype. Third, the gene expression phenotype of tumor cells could be linked to molecular-targeted therapies and drug combinations. The presence of two tumor subpopulations with mutually exclusive EGFR or SRC signaling pathways facilitated the prediction of drug combinations, for which the efficacy was validated using a patient-derived tumor xenograft mouse model [5]. In addition, tumor cell-specific expression of a drug target may reinforce the utilization of genome-based molecular-targeted therapy [55]. Fourth, immune cell profiling demonstrated that T cell or myeloid cell phenotypes influenced the success of immune checkpoint therapies. In the past decade, remarkable responses to immune checkpoint therapy (ICT) using therapeutic agents such as programmed death-1/programmed death ligand-1 (PD-1/PD-L1) and cytotoxic T lymphocyte antigen-4 (CTLA4) inhibitors have
been reported to have a huge impact on the management of cancer and development of cancer immunotherapies. Melanoma and lung cancer were the first tumor types against which ICT had shown efficacy; however, the overall response rate in these types was found to be less than 20%. Patient selection based on high PD-L1 expression—identified by immunohistochemistry or high TMB (or tumor neoantigen)—has increased the response rate to 40–60% [56]. As PD-L1 expression and high TMB resulted in the recapitulation of the immune cell-rich phenotype, immune profiling of the peripheral blood or tumor-infiltrating leukocytes (TILs) also predicted the response to ICT at some levels [57]. Nonetheless, this prediction is insufficient, and improved prediction methods could increase the success rate of ICT and aid the development of new strategies targeted at promoting tumor-directed immunity. In the single-cell genomic approach, immune cell profiling can be achieved at a much higher resolution, covering both cell types and cellular states (Table 3).

Table 3. Single-cell studies identifying immune cells associated with response to immune checkpoint inhibitor.

| Tumor Type       | Sample Source | Technology | Cell Subset                  | Association                                                                 | References |
|------------------|---------------|------------|------------------------------|----------------------------------------------------------------------------|------------|
| Melanoma         | TILs          | Flow cytometry | PD-1 hi CTLA-4 hi CD8+ T cell | Relative abundance of PD-1hiCTLA-4hi cells within the tumor-infiltrating CD8+ T cell subset correlates with response to checkpoint inhibitors and survival. | [58]       |
| Melanoma         | PBMCs, TILs   | Flow cytometry | Tex cell                    | Exhausted-phenotype CD8+ T (Tex) cells in relation to tumor burden correlates with clinical response to PD-1 blockade. | [59]       |
| NSCLC            | PBMCs         | Flow cytometry | PD-1+ CD8+ T cell           | PD-1+ CD8+ T cell in peripheral blood correlates with clinical benefit after receiving PD-1-targeted therapies. | [60]       |
| Melanoma         | TILs          | RNA-seq     | ICOS+ Th1-like CD4 effector cell | Anti-PD-1 induces the expansion of tumor-infiltrating exhausted-like CD8+ T cells (Tex), but anti-CTLA-4 induces the expansion of the ICOS+ Th1-like CD4 effector cells in addition to Tex cells. The presence of CD8+ T lymphocyte with high PD-1 expression is strongly predictive for response to PD-1 blockade and better survival. | [61]       |
| NSCLC            | TILs          | Flow cytometry | PD-1+ CD8+ T cell           | The presence of TCF7+ CD8+ T cells predicts response to checkpoint inhibitors and positive clinical outcome. | [62]       |
| Melanoma         | tumor         | scRNA-seq; ATAC-seq | TCF7+ CD8+ T cell | EOMES+CD69+CD45RO+ effector memory T cell phenotype is associated with response to checkpoint inhibitors and longer survival. | [63]       |
| Melanoma         | tumor         | RNA-seq; Multiplex IHC; CyTOF | EOMES+CD69+CD45RO+ effector memory T cell | The presence of CD8A+ tissue-resident T cells is associated with response to immune checkpoint blockade and improved survival. | [64]       |
| Melanoma; Head&Neck; Breast; Urothelial; Renal; Lung; Colorectal cancer | TILs, PBMCs | Flow cytometry; RNA-seq | Tex cell | Clonal TMB and CXCL9/CXCL10 expression in tumor-infiltrating CD8+ T cells predicts response to checkpoint blockade. | [65]       |
| Renal cell carcinoma | tumor lymph node PBMCs | RNA-seq; scRNA-seq | CXCL9/CXCL13 CD8+ T cell | The abundance of CD8A+ tissue-resident T cells is associated with response to immune checkpoint blockade and improved survival. | [66]       |
| Gastric cancer   | tumor         | scRNA-seq   | PD-1+ CD8+ T cell           | The abundance of PD-1+ CD8+ T cells correlates with response and longer survival to PD-1 blockade. | [67]       |

Comparison between responders and non-responders provides critical information regarding patient stratification and the mechanism of action of ICT [69]. Characterization of post-treatment samples helps define the immune cell dynamics and state transitions [70]. Overall, effector-memory CD8+ T cells are known to be associated with a positive response to ICT [61,64]. Exhausted phenotype T cells, likely including both activated and exhausted populations, have been reported to predict a positive ICT response in melanoma, NSCLC, and basal cell carcinoma [58–62,65,71,72]. In a more recent study, Transcription Factor 7 (TCF7)—but not PDCD1 (PD-1 gene)—expression, was found to be a positive predictor of tumor regression in melanoma [63]. In MSI-high gastric cancer, a diverse T cell receptor (TCR) repertoire and the presence of early-to-intermediate activation status T cells in tumor tissues were found to be associated with an ICT response [68]. As T cell activation and exhaustion are confounding processes, exhaustion markers are good indicators of...
the presence of tumor-directed immunity; however, terminal differentiation of collective tumor-specific T cells in the exhausted state may adversely influence the ICT response. Single-cell genomics is a robust tool for defining the dynamic balance between T cell activation and exhaustion.

Figure 2. Gene expression heterogeneity in cancer addressed by scRNA-seq.

4. Multimodal and Deconvolution Approaches Facilitate the Biological Interpretations and Clinical Applications of Single-Cell Genomic Data

Among many single-cell genomic tools, transcriptome analysis is most frequently used to evaluate intratumoral heterogeneity due to the scalability of technology and the feasibility of phenotypic translation. Several attributes need to be considered to exploit the biological and clinical interpretations of single-cell transcriptome data (Figure 3).

Both genetic and non-genetic mechanisms are likely to influence heterogeneity at the level of gene expression. Heterogeneity arising from tumor-intrinsic genetic evolution or non-genetic alterations triggered by microenvironmental factors is associated with distinct indications that enable the heterogeneity-associated treatment resistance to be overcome, depending on the source. Thus, linking genetic data with gene expression heterogeneity is
important to determine how to use the information for therapeutic advancement. Another important aspect of single-cell transcriptome analysis is the uncertainty in the number of clusters or subpopulations. Defining biologically meaningful clusters requires prior knowledge of gene expression obtained using well-isolated population data with functional corroboration. As the isolation procedures rely on a few surface protein markers, it is often the protein expression profile that defines a functional subpopulation. Therefore, the inference of transcriptome-based clusters needs to be validated by the simultaneous measurement of corresponding surface markers and gene expression. Finally, the use of single-cell RNA sequencing has practical limitations in terms of the cost and the associated sampling breadth. Though the cost has dropped substantially—and will continue to decrease—and the sampling breadth has increased, the output cell numbers in most studies remain below 3000 cells per sample, which may not be enough to cover extensive heterogeneity in complex tissues. Deconvolution methods using bulk genomic data—both at the genetic and the gene expression levels—may overcome the limitations associated with cost and sampling and could also provide an opportunity to treat a large number of patients besides offering substantial clinical annotations.

4.1. Linking Genetic and Gene Expression Data

Combining single-cell DNA and gene expression data may reveal tumor heterogeneity that could result in the translation of genetic evolution into transcriptional phenotypes. Multi-omics data generation methods [73] such as G&Tseq [74] and Trioseq [75]. Alternatively, genetic features, such as mutations and CNA, can be measured or inferred from scRNA-seq data (Table 4).

Table 4. Genetic features assessed by scRNA-seq.

| Genetic Feature | Method | Tool Name | References |
|-----------------|--------|-----------|------------|
| CNA             | chromosomal gene expression pattern | inferCNV [76] and copyKAT [77] | [https://github.com/broadinstitute/inferCNV, accessed on 15 July 2021](https://github.com/broadinstitute/inferCNV, accessed on 15 July 2021) |
|                 |        | CaSpER [77] and HoneyBADGER [78] |            |
|                 |        | scCNAutils [79] and CONICS [80] |            |
| Mutation        | targeted genotyping of cDNA | GoT [81] | [GoT](https://github.com/broadinstitute/goat) |
|                 | statistical method | SCMut [82] and DENDRO [83] | |

Detection of SNVs in single-cell RNA sequencing data is hampered by false negatives and positives caused by massive dropouts and amplification errors, respectively. Statistical methods may improve the detection accuracy to some extent [82,83]. Nonetheless, many single-cell RNA sequencing data do not cover full-length transcripts, and sequence variation analysis at specific sites remains an inefficient method to determine the clonality of tumor cells, even with full-length data. Inference of DNA CNAs from quantitative chromosomal gene expression data could provide a more robust method to identify genetic clones with large CNAs [76–80]. The supplementary use of single nucleotide polymorphisms (SNPs) increases the resolution of copy number inference and reconstruction of the clonal architecture [77,78].

CNA inference from single-cell gene expression data revealed that clonal evolution accompanies transcriptional heterogeneity in multiple cancer types, including myeloma, breast cancer, and glioblastoma [76,78,80]. In these studies, the genetic evolution potentially leading to the phenotype transition of tumor cells toward metastasis and treatment resistance could be identified. Transcriptional heterogeneity that is not recapitulated at the CNA level may indicate incomplete inference, other genomic events, and/or influences from microenvironmental factors.
4.2. Linking Protein and Gene Expression Clusters to the Functional Phenotype through Multi-Omic Analyses

The inference obtained from transcriptional clusters and a sparse gene expression necessitates cluster validation at the protein level, which might be provided by independent analyses such as flow cytometry or mass cytometry. Ideally, the use of antibody-derived tag (ADT) labeling cell surface proteins together with scRNA-seq [84,85] would result in the demarcation of transcriptional clusters linked to protein marker-defined subpopulations. As the ADT method is dependent on the specific binding of antibodies, combined usage with gene expression results in the generation of more reliable reference cell types [86]. An additional data type, i.e., chromatin accessibility, allows for a more refined cell type or cell state classification [87]. The direct projection of transcriptional clusters onto the functional phenotype can be achieved by single-cell clustered regularly interspaced short palindromic repeat (CRISPR) screening [87–89]. Moreover, spatial profiling using single-cell or spatial transcriptomics [90,91] uncovers the location of specific cell populations and their neighbors, further refining cellular identities and substantiating cellular interactions. Overall, multimodal data bridge biomarkers (from any data type) and functional phenotypes, help refine the cell type and cell state annotations, and allow for a mechanistic dissection for phenotype control.

4.3. Linking Single-Cell Gene Expression Data to Clinical Output through Bulk Deconvolution

Despite the high-resolution cell type or transcriptional state information, the availability of single-cell gene expression data with clinical annotations is limited when compared to the bulk tissue-level data. Therefore, once cellular characteristics are defined at a single-cell resolution, tissue-level gene expression data are used to validate the clinical significance of the findings from the single-cell data. (Table 5 and Figure 4).

| Tumor Type                        | Deconvolution Approaches                                                                 | Main Findings                                                                 | References |
|-----------------------------------|------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|------------|
| Triple negative breast cancer     | Inference of tissue-resident memory T (Trm) gene signature expression level               | Association with improved patient survival rate in early-stage TNBC            | [92]       |
| Melanoma                          | Inference of T cell infiltration levels and malignant genes correlated with T cell infiltration | Genes associated with T cell exclusion program                                | [70]       |
| Nasopharyngeal carcinoma          | Correlations of 17 immune subtype signatures with clinicopathological features           | Immune subsets significantly associated with better survival outcomes         | [93]       |
| Gastric cancer                    | Inference of M2-like TAM level                                                           | Improved prediction of poor survival by high M2 signature                     | [94]       |

**Table 5.** Tumor studies using scRNA-seq data for bulk RNA-seq deconvolution.

First, deconvolution approaches would facilitate the inference of the cell type composition from the bulk gene expression data. Performance testing of different deconvolution methods using pseudo-bulk single-cell RNA sequencing data demonstrated that linear data transformation, an all-inclusive reference matrix, and sensible marker selection are required to achieve high concordance between the proportions of expected and calculated cell types [100]. The resolution of deconvolution approaches is confined to well-defined global cell types, whereas single-cell data allow for a fine subpopulation analysis with distinct and even transitional transcription states. The second approach involves correlation
or enrichment analysis of gene expression signatures derived from a subpopulation in the single-cell data. In this approach, correlation or enrichment scores are used to portray bulk gene expression data, with more flexibility than the deconvolution approaches. Cancer cell programs [70] and immune cell programs [101,102] derived from single-cell data have been utilized to evaluate bulk datasets and are linked to clinical disease courses. As more scRNA-seq data are generated with clinical annotations, direct comparisons of fine cellular dynamics and disease courses will become available.

**Figure 4.** Strategies linking single cell gene expression analysis and bulk-level clinical data.

### 4.4. Using BCR and TCR Data for Lineage Tracing and Therapeutic Development

Single-cell RNA sequencing analysis has revealed the whole combinatorial sequences of BCR and TCR allow for the lineage tracing of clonal B/plasma cells and T cells, respectively. Lineage tracing involves direct comparison of a patient’s T cells collected from different regions, such as the blood and the normal and tumor tissues, as well as the T cells at various differentiation stages. Through simultaneous gene expression and TCR analyses, high levels of clonal expansion have been identified in cytotoxic T cells from normal tissues and exhausted/cytotoxic T cells from tumor tissues [103,104]. Clonal expansion of tumor-infiltrating T cells suggests a potential tumor reactivity that might be further propagated by immune checkpoint inhibitors. In addition to tracking T cell or antibody responses, TCR or BCR sequences may also be used for the development of novel treatments in the future. Therapeutic antibody development using this reversal approach has been adopted in non-cancer conditions such as COVID-19 infection or vaccination [105,106], where antigenic specificity can be easily tested. Finding tumor antigen specificities is a challenging task and currently limits the direct use of BCR or TCR sequences.

### 5. Conclusions

Single-cell genomics enables the fine-tuning of cancer genomics to a cellular resolution and broadens the scope of cancer cell biology to the genomic scale. For cellular and molecular dissection, various experimental and analytical methods have been developed to specify the cell types and states that matter, and to enable the molecular features that characterize heterogeneous tumor cells to be distinguished from those characterizing the support cells in the tumor microenvironment. Diverse cell populations comprising tumor...
tissues are not randomly recruited, as they are likely to communicate with each other and form a network that determines the cellular and the molecular landscapes of tumor tissues as an entity \cite{107,108}. The molecular characteristics of each cellular component and its interconnections—either promoting or inhibiting tumor growth—are all points that can be leveraged during therapeutic development. Therefore, single-cell genomics and the related multi-omics technologies are exploratory tools that far exceed the scope and effectiveness of preceding bulk genomic analyses.

Beyond being an exploratory tool, single-cell genomics has limited capacity as a field technology for detecting tumor heterogeneity in precision oncology. This limitation is attributed to the current sampling breadth, which may result in a partial representation of the whole tumor. For rare CTCs and residual tumors, single-cell genomics facilitated genomic characterization by enabling partial DNA or RNA analyses. Nonetheless, capturing CTCs and residual tumors requires a very large number of cells—up to billions—for analysis or a high-fold enrichment of target populations. However, single-cell genomics technology represents a very active field of research that links single-cell data directly to the clinical decision-making process.

Author Contributions: Conceptualization, H.-O.L.; writing—original draft preparation, N.K., H.H.E., H.-O.L.; writing—review and editing, N.K., H.H.E., H.-O.L.; visualization, N.K., H.H.E.; supervision, H.-O.L.; project administration, H.-O.L.; funding acquisition, H.-O.L. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by National Research Foundation (NRF) funded by the Ministry of Science & ICT (MSIT), grant number NRF-2017M3C9A6044636 and 2019M3A9B6064691. N.K. and H.H.E. are supported by Basic Science Research Program through NRF funded by the Ministry of Education (NRF-2020R1I1A1A01065697 and NRF-2021R1I1A1A01043906).

Acknowledgments: Discussion and technical comments from Areum Jo and Dasom Jeong (The Catholic University of Korea).

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References
1. Patel, A.P.; Tirosh, I.; Trombetta, J.J.; Shalek, A.K.; Gillespie, S.M.; Wakimoto, H.; Cahill, D.P.; Nahed, B.V.; Currie, W.T.; Martuza, R.L.; et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 2014, 344, 1396–1401. [CrossRef] [PubMed]
2. Tirosh, I.; Izar, B.; Prakadan, S.M.; Wadsworth, M.H., 2nd; Treacy, D.; Trombetta, J.J.; Rotem, A.; Rodman, C.; Lian, C.; Murphy, G.; et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 2016, 352, 189–196. [CrossRef]
3. Aissa, A.F.; Islam, A.; Arias, M.M.; Go, C.C.; Rader, A.E.; Conardly, R.D.; Gajda, A.M.; Rubio-Perez, C.; Valri-Nagy, K.; Pasquinelli, M.; et al. Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer. Nat. Commun. 2021, 12, 1628. [CrossRef]
4. Kim, K.T.; Lee, H.W.; Lee, H.O.; Kim, S.C.; Seo, Y.J.; Chung, W.; Eum, H.H.; Nam, D.H.; Kim, J.; Joo, K.M.; et al. Single-cell mRNA sequencing identifies subclonal heterogeneity in anti-cancer drug responses of lung adenocarcinoma cells. Genome Biol. 2015, 16, 127. [CrossRef] [PubMed]
5. Kim, K.T.; Lee, H.W.; Lee, H.O.; Song, H.J.; Jeong, D.E.; Shin, S.; Kim, H.; Shin, Y.; Nam, D.H.; Jeong, B.C.; et al. Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma. Genome Biol. 2016, 17, 80. [CrossRef] [PubMed]
6. Butler, A.; Hoffman, P.; Smibert, P.; Papalexi, E.; Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 2018, 36, 411–420. [CrossRef] [PubMed]
7. Braun, T.P.; Eide, C.A.; Druker, B.J. Response and Resistance to BCR-ABL1-Targeted Therapies. Cancer Cell 2020, 37, 530–542. [CrossRef] [PubMed]
8. Druker, B.J.; Talpaz, M.; Resta, D.J.; Peng, B.; Buchdunger, E.; Ford, J.M.; Lydon, N.B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001, 344, 1031–1037. [CrossRef]
9. International Cancer Genome Consortium; Hudson, T.J.; Anderson, W.; Artez, A.; Barker, A.D.; Bell, C.; Bernabe, R.R.; Bhan, M.K.; Calvo, F.; Eerola, I.; et al. International network of cancer genome projects. Nature 2010, 464, 993–998. [CrossRef]
10. Cancer Genome Atlas (TCGA) Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455, 1061–1068. [CrossRef] [PubMed]

11. Gao, G.F.; Parker, J.S.; Reynolds, S.M.; Silva, T.C.; Wang, L.B.; Zhou, W.; Akbani, R.; Bailey, M.; Balu, S.; Berman, B.P.; et al. Before and After: Comparison of Legacy and Harmonized TCGA Genomic Data Commons’ Data. Cell Syst. 2019, 9, 24–34.e10. [CrossRef] [PubMed]

12. Mosele, F.; Remon, J.; Mateo, J.; Westphalen, C.B.; Barlesi, F.; Lolkema, M.P.; Normanno, N.; Scarpa, A.; Robson, M.; Meric-Bernstam, F.; et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group. Ann. Oncol. 2020, 31, 1491–1505. [CrossRef] [PubMed]

13. Zhong, Y.; Xu, F.; Wu, J.; Schubert, J.; Li, M.M. Application of Next Generation Sequencing in Laboratory Medicine. Ann. Lab. Med. 2021, 41, 25–43. [CrossRef] [PubMed]

14. Perakis, S.O.; Weber, S.; Zhou, Q.; Graf, R.; Hojas, S.; Riedl, J.M.; Gerger, A.; Dandachi, N.; Balic, M.; Hoefler, G.; et al. Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer. ESMO Open 2020, 5, e000872. [CrossRef] [PubMed]

15. Tate, J.G.; Bamford, S.; Jubb, H.C.; Sondka, Z.; Beare, D.M.; Bindal, N.; Boutsalakis, H.; Cole, C.G.; Creature, C.; Dawson, E.; et al. COSMIC: The Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2019, 47, D941–D947. [CrossRef]

16. De Jesus, S.; Almeida, L.; Peng-Chen, Z.; Okun, M.S.; Hess, C.W. Novel targets and stimulation paradigms for deep brain stimulation. Expert Rev. Neurother. 2015, 15, 1067–1080. [CrossRef]

17. Goldberg, K.B.; Blumenthal, G.M.; Pazdur, R. The First Year of the Food and Drug Administration Oncology Center of Excellence: Landmark Approvals in a Dynamic Regulatory Environment. Cancer J. 2018, 24, 131–135. [CrossRef] [PubMed]

18. Cocco, E.; Scaltriti, M.; Drilon, A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat. Rev. Clin. Oncol. 2018, 15, 731–747. [CrossRef]

19. Bartlett, J.M.; Bayani, J.; Marshall, A.; Dunn, J.A.; Campbell, A.; Cunningham, C.; Sobol, M.S.; Hall, P.S.; Poole, C.J.; Cameron, D.A.; et al. Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others. J. Natl. Cancer Inst. 2016, 108. [CrossRef] [PubMed]

20. Ross, J.S.; Hatzis, C.; Symmans, W.F.; Pusztai, L.; Hortobagyi, G.N. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 2008, 13, 477–493. [CrossRef] [PubMed]

21. Shaughnessy, J.D., Jr.; Zhan, F.; Burington, B.E.; Huang, Y.; Colla, S.; Hanamura, I.; Stewart, J.P.; Kordsmeier, B.; Randolph, C.; Williams, D.R.; et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007, 109, 2276–2284. [CrossRef] [PubMed]

22. Kuiper, R.; Broyl, A.; de Knegt, Y.; van Vliet, M.H.; van der Holt, B.; van der Jarari, L.; Mulligan, G.; Gregory, W.; Morgan, G.; et al. A gene expression signature for high-risk multiple myeloma. Leukemia 2012, 26, 2406–2413. [CrossRef]

23. Dagogo-Jack, I.; Shaw, A.T. Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol. 2018, 15, 81–94. [CrossRef] [PubMed]

24. Gerlinger, M.; Rowan, A.J.; Horswell, S.; Math, M.; Larkin, J.; Endesfelder, D.; Gronroos, E.; Martinez, P.; Matthews, N.; Stewart, A.; et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366, 883–892. [CrossRef] [PubMed]

25. Jamal-Hanjani, M.; Wilson, G.A.; McGranahan, N.; Birkbak, N.J.; Watkins, T.B.K.; Veeriah, S.; Shafi, S.; Johnson, D.H.; Mitter, R.; Rosenthal, R.; et al. Tracking the Evolution of Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2017, 376, 2109–2121. [CrossRef] [PubMed]

26. Lee, J.K.; Wang, J.; Sa, J.K.; Ladewig, E.; Lee, H.O.; Lee, I.H.; Kang, H.J.; Rosenbloom, D.S.; Camara, P.G.; Liu, Z.; et al. Spatiotemporal genomic architecture informs precision oncology in glioblastoma. Nat. Genet. 2017, 49, 594–599. [CrossRef] [PubMed]

27. Abduljabbar, K.; Raza, S.E.A.; Rosenthal, R.; Jamal-Hanjani, M.; Veeriah, S.; Akarca, A.; Lund, T.; Moore, D.A.; Salgado, R.; Al Bakir, M.; et al. Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. Nat. Med. 2020, 26, 1054–1062. [CrossRef] [PubMed]

28. Biswas, D.; Birkbak, N.J.; Rosenthal, R.; Hiley, C.T.; Lim, E.L.; Papp, K.; Boeing, S.; Krzystanek, M.; Djureinovic, D.; La Fleur, L.; et al. A clonal expression biomarker associates with lung cancer mortality. Nat. Med. 2019, 25, 1540–1548. [CrossRef]

29. Chemi, F.; Rothwell, D.G.; McGranahan, N.; Gulati, S.; Abbosh, C.; Pearce, S.P.; Zhou, C.; Wilson, G.A.; Jamal-Hanjani, M.; Birkbak, N.; et al. Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. Nat. Med. 2019, 25, 1534–1539. [CrossRef]

30. Ghorani, E.; Reading, J.L.; Henry, J.Y.; de Massy, M.R.; Rosenthal, R.; Turati, V.; Joshi, K.; Furness, A.J.S.; Aissa, A.B.; Saini, S.K.; et al. The T cell differentiation landscape is shaped by tumour mutations in lung cancer. Nat. Cancer 2020, 1, 546–561. [CrossRef]

31. Joshi, K.; de Massy, M.R.; Ismail, M.; Reading, J.L.; Uddin, I.; Woolston, A.; Hatipoglu, E.; Oakes, T.; Rosenthal, R.; Peacock, T.; et al. Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. Nat. Med. 2019, 25, 1549–1559. [CrossRef]

32. Lopez, S.; Lim, E.L.; Horswell, S.; Haase, K.; Huebner, A.; Dietzen, M.; Mourikis, T.P.; Watkins, T.B.K.; Rowan, A.; Dewhurst, S.M.; et al. Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution. Nat. Genet. 2020, 52, 283–293. [CrossRef] [PubMed]
33. Rosenthal, R.; Cadieux, E.L.; Salgado, R.; Bakir, M.A.; Moore, D.A.; Hiley, C.T.; Lund, T.; Tanic, M.; Reading, J.L.; Joshi, K.; et al. Neoantigen-directed immune escape in lung cancer evolution. *Nature* 2019, 567, 479–485. [CrossRef] [PubMed]

34. Tarabichi, M.; Salcedo, A.; Deshwat, A.G.; Ni Leathlobhain, M.; Wintersinger, J.; Wedge, D.C.; Van Loo, P.; Morris, Q.D.; Boutros, P.C. A practical guide to cancer subclonal reconstruction from DNA sequencing. *Nat. Methods* 2021, 18, 144–155. [CrossRef]

35. Andor, N.; Graham, T.A.; Jansen, M.; Xia, L.C.; Aktipis, C.A.; Petritsch, C.; Ji, H.P.; Maley, C.C. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. *Nat. Med.* 2016, 22, 105–113. [CrossRef]

36. Espiritu, S.M.G.; Liu, L.Y.; Rubanova, Y.; Bhandari, V.; Holgersen, E.M.; Szyca, L.M.; Fox, N.S.; Chua, M.L.K.; Yamaguchi, T.N.; Heiser, L.E.; et al. The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression. *Cell* 2018, 173, 1003–1013.e1015. [CrossRef]

37. Mallory, X.F.; Edrissi, M.; Navin, N.; Nakhleh, L. Methods for copy number aberration detection from single-cell DNA-sequencing data. *Genome Biol.* 2020, 21, 208. [CrossRef] [PubMed]

38. Minussi, D.C.; Nicholson, M.D.; Ye, H.; Davis, A.; Wang, K.; Baker, T.; Tarabichi, M.; Sei, E.; Du, H.; Rabbani, M.; et al. Breast tumours maintain a reservoir of subclonal heterogeneity across disease stages and during expansion. *Nature* 2021, 592, 302–308. [CrossRef] [PubMed]

39. Pantel, K.; Alix-Panabieres, C. Liquid biopsy and minimal residual disease—Latest advances and implications for cure. *Nat. Rev. Clin. Oncol.* 2019, 16, 409–424. [CrossRef] [PubMed]

40. Edirwickrema, A.; Aleshin, A.; Reiter, J.G.; Corces, M.R.; Kohnke, T.; Stafford, M.; Medeiros, B.C.; Majeti, R. Single-cell mutational profiling enhances the clinical evaluation of AML. *MRD. Blood Adv.* 2020, 4, 943–952. [CrossRef] [PubMed]

41. Guinney, J.; Dienstmann, R.; Wang, X.; de Reynie, A.; Schlicker, A.; Soneson, C.; Marisa, L.; Roepman, P.; Nyamundanda, G.; Angelino, P.; et al. The consensus molecular subtypes of colorectal cancer. *Nat. Med.* 2015, 21, 1330–1336. [CrossRef] [PubMed]

42. Verhaak, R.G.; Hoadley, K.A.; Sengupta, D.; Tan, Y.; Chen, K.H.; Goh, J.J.L.; Kong, S.L.; Chua, C.; Hon, L.K.; Tan, W.S.; et al. Reference RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. *Nat. Commun.* 2020, 11, 960–970. [CrossRef]

43. Weigelt, B.; Mackay, A.; A’Hern, R.; Natrajan, R.; Tan, D.S.; Dowsett, M.; Ashworth, A.; Reis-Filho, J.S. Breast cancer molecular profiling with single sample predictors: A retrospective analysis. *Lancet Oncol.* 2010, 11, 339–349. [CrossRef]

44. Gonzalez Castro, L.N.; Tirosh, I.; Suva, M.L. Decoding Cancer Biology One Cell at a Time. *Cancer Discov.* 2021, 11, 960–970. [CrossRef]

45. Kim, N.; Kim, H.K.; Lee, K.; Hong, Y.; Cho, J.H.; Choi, J.W.; Lee, J.I.; Suh, Y.L.; Ku, B.M.; Eum, H.H.; et al. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. *Nat. Commun.* 2020, 11, 2285. [CrossRef]

46. Wu, F.; Fan, J.; He, Y.; Xiong, A.; Yu, J.; Li, Y.; Zhang, Y.; Zhao, W.; Zhou, F.; Li, W.; et al. Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. *Nat. Commun.* 2021, 12, 2540. [CrossRef]

47. Wang, Y.; Waters, J.; Leung, M.L.; Hiley, C.T.; Lund, T.; Tanic, M.; Reading, J.L.; Joshi, K.; et al. Description of a single-cell landscape of high-grade serous ovarian cancer. *Nat. Med.* 2020, 26, 1271–1279. [CrossRef] [PubMed]

48. Nefelt, C.; Laffy, J.; Filbin, M.G.; Shore, M.E.; Rahme, G.J.; Richman, A.R.; Silverbush, D.; Shaw, M.L.; Hebert, C.M.; et al. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. *Cell* 2019, 178, 835–849.e821. [CrossRef]

49. Puram, S.V.; Tirosh, I.; Parikh, A.S.; Patel, A.P.; Yizhak, K.; Gillespie, S.; Rodman, C.; Luo, C.L.; Mroz, E.A.; Emerick, K.S.; et al. Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer. *Cell* 2018, 173, 879–893.e813. [CrossRef] [PubMed]

50. Lee, H.O.; Hong, Y.; Etioglu, H.E.; Cho, Y.B.; Pomella, V.; Van den Bosch, B.; Vanhecke, J.; Verbandt, S.; Hong, H.; Min, J.W.; et al. Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer. *Nat. Genet.* 2020, 52, 594–603. [CrossRef] [PubMed]

51. Izar, B.; Tirosh, I.; Stover, E.H.; Wakiro, I.; Cuoco, M.S.; Alter, I.; Rodman, C.; Leeson, R.; Su, M.J.; Shah, P.; et al. Single-cell profiling of tumor heterogeneity and immune cell profiling in primary breast cancer. *Nat. Commun.* 2017, 8, 15081. [CrossRef] [PubMed]

52. Lee, H.W.; Chung, W.; Lee, H.O.; Jeong, D.E.; Jo, A.; Lim, J.E.; Hong, J.H.; Nam, D.H.; Jeong, B.C.; Park, S.H.; et al. Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient. *Genome Med.* 2020, 12, 47. [CrossRef]

53. Yarchan, M.; Albacker, L.A.; Hopkins, A.C.; Montesion, M.; Murugesan, K.; Vithayathil, T.T.; Zaidi, N.; Azad, N.S.; Laheru, D.A.; Frampton, G.M.; et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. *JCI Insight* 2019, 4. [CrossRef]

54. Darwin, P.; Toor, S.M.; Sasidharan Nair, V.; Elkord, E. Immune checkpoint inhibitors: Recent progress and potential biomarkers. *Exp. Mol. Med.* 2018, 50, 1–11. [CrossRef] [PubMed]
58. Daud, A.I.; Loo, K.; Pauli, M.L.; Sanchez-Rodriguez, R.; Sandoval, P.M.; Taravati, K.; Tsai, K.; Nosrati, A.; Nardo, L.; Alvarado, M.D.; et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J. Clin. Investig. 2016, 126, 3447–3452. [CrossRef] [PubMed]

59. Huang, A.C.; Postow, M.A.; Orlowksi, R.J.; Mick, R.; Bengsch, B.; Manne, S.; Xu, W.; Harmon, S.; Giles, J.R.; Wenz, B.; et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 2017, 545, 60–65. [CrossRef] [PubMed]

60. Kamphorst, A.O.; Pillai, R.N.; Yang, S.; Nasti, T.H.; Akondy, R.S.; Wieland, A.; Sica, G.L.; Yu, K.; Koenig, L.; Patel, N.T.; et al. Proliferation of PD-1+ CD8+ T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc. Natl. Acad. Sci. USA 2017, 114, 4993–4998. [CrossRef] [PubMed]

61. Wei, S.C.; Levine, J.H.; Cogdill, A.P.; Zhao, Y.; Anang, N.A.S.; Andrews, M.C.; Sharma, P.; Wang, J.; Wargo, J.A.; Pe'er, D.; et al. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell 2017, 170, 1120–1133.e1117. [CrossRef] [PubMed]

62. Thommen, D.S.; Koelzer, V.H.; Herzig, P.; Roller, A.; Trefny, M.; Dimeloe, S.; Kiialainen, A.; Hanhart, J.; Schill, C.; Hess, C.; et al. A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat. Med. 2018, 24, 994–1004. [CrossRef] [PubMed]

63. Sade-Feldman, M.; Yizhak, K.; Bjorgaard, S.L.; Ray, J.P.; de Boer, C.G.; Jenkins, R.W.; Lieb, D.J.; Chen, J.H.; Frederick, D.T.; Barzily-Rokni, M.; et al. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell 2019, 176, 404. [CrossRef] [PubMed]

64. Gide, T.N.; Quec, K.; Menzies, A.M.; Tasker, A.T.; Shang, P.; Holst, J.; Madore, J.; Lim, S.Y.; Velickovic, R.; Wongchenko, M.; et al. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Cancer Cell 2019, 35, 238–255.e236. [CrossRef] [PubMed]

65. Huang, A.C.; Orlowksi, R.J.; Xu, X.; Mick, R.; George, S.M.; Yan, P.K.; Manne, S.; Kraya, A.A.; Wubbenhorst, B.; Dorfman, L.; et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat. Med. 2019, 25, 454–461. [CrossRef] [PubMed]

66. Litchfield, K.; Reading, J.L.; Puttick, C.; Thakkar, K.; Abbosh, C.; Bentham, R.; Watkins, T.B.K.; Biswas, D.; Rowan, A.; et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 2021, 184, 596–614.e514. [CrossRef] [PubMed]

67. Krishna, C.; DiNatale, R.G.; Kuo, F.; Srivastava, R.M.; Vuong, L.; Chowell, D.; Gupta, S.; Vanderbilt, C.; Purohit, T.A.; Liu, M.; et al. Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy. Cancer Cell 2019, 39, 662–677.e666. [CrossRef] [PubMed]

68. Kwon, M.; An, M.; Klemperner, S.J.; Lee, H.; Kim, K.M.; Sa, J.K.; Cho, H.J.; Hong, J.Y.; Lee, T.; Min, Y.W.; et al. Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer. Cancer Discov. 2021. [CrossRef] [PubMed]

69. Sade-Feldman, M.; Yizhak, K.; Bjorgaard, S.L.; Ray, J.P.; de Boer, C.G.; Jenkins, R.W.; Lieb, D.J.; Chen, J.H.; Frederick, D.T.; Barzily-Rokni, M.; et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 2018, 24, 998–1013.e1020. [CrossRef] [PubMed]

70. Jerby-Aron, L.; Shah, P.; Cuoco, M.S.; Rodman, C.; Su, M.J.; Leeson, R.; Kanodia, A.; Mei, S.; Lin, J.R.; et al. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell 2018, 175, 984–997.e924. [CrossRef] [PubMed]

71. Satpathy, A.T.; Granja, J.M.; Yost, K.E.; Qi, Y.; Meschi, F.; McDermott, G.P.; Olsen, B.N.; Mumbach, M.R.; Pierce, S.E.; Corces, M.R.; et al. Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion. Nat. Biotechnol. 2019, 37, 925–936. [CrossRef] [PubMed]

72. Yost, K.E.; Satpathy, A.T.; Wells, D.K.; Qi, Y.; Wang, C.; Kageyama, R.; McNamara, K.L.; Granja, J.M.; Sarin, K.Y.; Brown, R.A.; et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 2019, 25, 1251–1259. [CrossRef] [PubMed]

73. Lee, J.; Hyeon, D.Y.; Wang, D. Single-cell multomics: Technologies and data analysis methods. Exp. Mol. Med. 2020, 52, 1428–1442. [CrossRef] [PubMed]

74. Macaulay, I.C.; Haerty, W.; Kumar, P.; Li, Y.I.; Hu, T.X.; Teng, M.J.; Goolam, M.; Saurat, N.; Coupland, P.; Shirley, L.M.; et al. G&T-seq: Parallel sequencing of single-cell genomes and transcriptomes. Nat. Methods 2015, 12, 519–522. [CrossRef] [PubMed]

75. Bian, S.; Hou, Y.; Zhou, X.; Li, X.; Yong, J.; Wang, Y.; Wang, W.; Yan, J.; Hu, B.; Guo, H.; et al. Single-cell multomics sequencing and analyses of human colorectal cancer. Science 2018, 362, 1060–1063. [CrossRef] [PubMed]

76. Gao, R.; Bai, S.; Henderson, Y.C.; Lin, Y.; Schalck, A.; Yan, Y.; Kumar, T.; Hu, M.; Sei, E.; Davis, A.; et al. Delineating copy number and clonal substructure in human tumors from single-cell transcriptomes. Nat. Biotechnol. 2021, 39, 599–608. [CrossRef] [PubMed]

77. Serin Harmanci, A.; Harmanci, A.O.; Zhou, X. CaSpER identifies and visualizes CNV events by integrative analysis of single-cell or bulk RNA-sequencing data. Nat. Commun. 2020, 11, 89. [CrossRef] [PubMed]

78. Fan, J.; Lee, H.O.; Lee, S.; Ryu, D.E.; Lee, S.; Xue, C.; Kim, S.J.; Kim, K.; Barkas, N.; Park, P.J.; et al. Linking transcriptional and genetic tumor heterogeneity through allele analysis of single-cell RNA-seq data. Genome Res. 2018, 28, 1217–1227. [CrossRef] [PubMed]

79. Couturier, C.P.; Ayyadhurst, S.; Le, P.U.; Nadaf, J.; Monlong, J.; Riva, G.; Allache, R.; Baig, S.; Yan, X.; Bourgey, M.; et al. Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy. Nat. Commun. 2020, 11, 3406. [CrossRef]
80. Muller, S.; Cho, A.; Liu, S.J.; Lim, D.A.; Diaz, A. CONICS integrates scRNA-seq with DNA sequencing to map gene expression to tumor sub-clones. *Bioinformatics* 2018, 34, 3217–3219. [CrossRef]

81. Nam, A.S.; Kim, K.T.; Chaligine, R.; Izzo, F.; Ang, C.; Taylor, J.; Myers, R.M.; Abu-Zeinah, G.; Brand, R.; Omans, N.D.; et al. Somatic mutations and cell identity linked by Genotyping of Transcriptomes. *Nature* 2019, 571, 355–360. [CrossRef] [PubMed]

82. Yu, T.N.; Nguyen, H.N.; Calza, S.; Kalari, K.R.; Wang, L.; Pawitan, Y. Cell-level somatic mutation detection from single-cell RNA sequencing. *Bioinformatics* 2019, 35, 4679–4687. [CrossRef]

83. Zhou, Z.; Xu, B.; Minn, A.; Zhang, N.R. DENDRO: Genetic heterogeneity profiling and subclone detection by single-cell RNA sequencing. *Genome Biol.* 2020, 21, 10. [CrossRef]

84. Peterson, V.M.; Zhang, K.X.; Kumar, N.; Wong, J.; Li, L.; Wilson, D.C.; Moore, R.; McLellan, T.K.; Sadekova, S.; Klappenbach, J.A. Multiplexed quantification of proteins and transcripts in single cells. *Nat. Biotechnol.* 2017, 35, 936–939. [CrossRef] [PubMed]

85. Sotek, M.; Hafemeister, C.; Stephenson, W.; Houck-Loomis, B.; Chattopadhyay, P.K.; Swerdlow, H.; Satija, R.; Smibert, P. Simultaneous epitope and transcriptome measurement in single cells. *Nat. Methods* 2017, 14, 865–868. [CrossRef] [PubMed]

86. Hao, Y.; Yao, S.; Andersen-Nissen, E.; Mauck, W.M.; 3rd; Zheng, S.; Butler, A.; Lee, M.J.; Wilk, A.J.; Darby, C.; Zager, M.; et al. Integrated analysis of multimodal single-cell data. *Cell* 2021, 184, 3573–3587.e3529. [CrossRef] [PubMed]

87. Mimitou, E.P.; Lareau, C.A.; Chen, K.Y.; Zorzetto-Fernandes, A.L.; Hao, Y.; Takeshima, Y.; Luo, W.; Huang, T.S.; Yeung, B.Z.; Nirschl, C.J.; Suarez-Farinas, M.; Izar, B.; Prakadan, S.; Dannenfelser, R.; Tirosh, I.; Liu, Y.; Zhu, Q.; Devi, K.S.P.; Carroll, S.L.; et al. Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens. *Nat. Genet.* 2021, 53, 322–331. [CrossRef] [PubMed]

88. Dixit, A.; Parnas, O.; Li, B.; Chen, J.; Falco, C.P.; Jerby-Arnon, L.; Marjanovic, N.D.; Dionne, D.; Burks, T.; Raychowdhury, R.; et al. Perturb-Seq: Dissecting Molecular Cues with Scalable Single-Cell RNA Profiling of Pooled Genetic Screens. *Cell* 2016, 167, 1853–1866.e1817. [CrossRef] [PubMed]

89. Papalexi, E.; Mimitou, E.P.; Butler, A.W.; Foster, S.; Bracken, B.; Mauck, W.M.; 3rd; Wessels, H.H.; Hao, Y.; Yeung, B.Z.; Smibert, P.; et al. Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens. *Nat. Genet.* 2019, 51, 896–903. [CrossRef] [PubMed]

90. Nagle, M.P.; Tam, G.S.; Maltz, E.; Hemminger, Z.; Wollman, R. Bridging scales: From cell biology to physiology using in situ single-cell technologies. *Cell Syst.* 2021, 12, 388–400. [CrossRef] [PubMed]

91. Rozenblatt-Rosen, O.; Shin, J.W.; Rood, J.E.; Hupalowska, A.; Human Cell Atlas Standards and Technology Working Group; Newman, A.M.; Steen, C.B.; Liu, C.L.; Gentles, A.J.; Chaudhuri, A.A.; Scherer, F.; Khodadoust, M.S.; Esfahani, M.S.; Luca, B.A.; Steiner, D.; et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. *Nat. Biotechnol.* 2019, 37, 773–782. [CrossRef] [PubMed]

92. Savas, P.; Virassamy, B.; Ye, C.; Salim, A.; Mintoff, C.P.; Caramia, F.; Salgado, R.; Byrne, D.J.; Teo, Z.L.; Dushyanthen, S.; et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. *Nat. Med.* 2018, 24, 986–993. [CrossRef] [PubMed]

93. Chen, Y.P.; Yin, J.H.; Li, W.F.; Li, H.J.; Chen, D.P.; Zhang, C.J.; Lv, J.W.; Wang, Y.Q.; Li, X.M.; Li, J.Y.; et al. Single-cell transcriptomics reveals regulators underlining immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma. *Cell Res.* 2020, 30, 1024–1042. [CrossRef]

94. Eum, H.H.; Kwon, M.; Ryu, D.; Jo, A.; Chung, W.; Kim, N.; Hong, Y.; Son, D.S.; Kim, S.T.; Lee, J.; et al. Tumor-promoting macrophages prevail in malignant ascites of advanced gastric cancer. *Exp. Mol. Med.* 2020, 52, 1976–1988. [CrossRef] [PubMed]

95. Newman, A.M.; Steen, C.B.; Liu, C.L.; Gentles, A.J.; Chaudhuri, A.A.; Scherer, F.; Khodadoust, M.S.; Esfahani, M.S.; Luca, B.A.; Steiner, D.; et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. *Nat. Biotechnol.* 2019, 37, 773–782. [CrossRef] [PubMed]

96. Dong, R.; Yang, R.; Zhan, Y.; Lai, H.D.; Ye, C.J.; Yao, X.Y.; Luo, W.Q.; Cheng, X.M.; Miao, J.J.; Wang, J.F.; et al. Single-Cell Characterization of Malignant Phenotypes and Developmental Trajectories of Adrenal Neuroblastoma. *Cancer Cell* 2020, 38, 716–733.e716. [CrossRef]

97. Chen, Z.; Zhou, L.; Liu, L.; Hou, Y.; Xiong, M.; Yang, Y.; Hu, J.; Chen, K. Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma. *Nat. Commun.* 2020, 11, 5077. [CrossRef] [PubMed]

98. Qi, Z.; Liu, Y.; Mints, M.; Mullins, R.; Sample, R.; Law, T.; Barrett, T.; Mazul, A.L.; Jackson, R.S.; Kang, S.Y.; et al. Single-Cell Deconvolution of Head and Neck Squamous Cell Carcinoma. *Cancers* 2021, 13, 1230. [CrossRef] [PubMed]

99. Ki, B.; He, M.X.; Bakouny, Z.; Kanodia, A.; Napolitano, S.; Wu, J.; Grimaldi, G.; Braun, D.A.; Cuoco, M.S.; Mayorga, A.; et al. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. *Cancer Cell* 2021, 39, 649–661.e645. [CrossRef] [PubMed]

100. Avila Cobos, F.; Alquicira-Hernandez, J.; Powell, J.E.; Mestdagh, P.; De Preter, K. Benchmarking of cell type deconvolution pipelines for transcriptomics data. *Nat. Commun.* 2020, 11, 5650. [CrossRef] [PubMed]

101. Li, H.; van der Leun, A.M.; Yofe, I.; Lubling, Y.; Gelbard-Solodkin, D.; van Akkooi, A.C.J.; van den Braber, M.; Rozeman, E.A.; Haanen, J.; Blank, C.U.; et al. Dysfunctional CDB T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma. *Cell* 2020, 181, 474. [CrossRef]

102. Nirschl, C.J.; Suarez-Farinaz, M.; Izar, B.; Prakadan, S.; Dannenfelser, R.; Tirosh, I.; Liu, Y.; Zhu, Q.; Devi, K.S.P.; Carroll, S.L.; et al. IFNgamma-Dependent Tissue-Immune Homeostasis Is Co-opted in the Tumor Microenvironment. *Cell* 2017, 170, 127–141.e115. [CrossRef]

103. Li, H.; van der Leun, A.M.; Yofe, I.; Lubling, Y.; Gelbard-Solodkin, D.; van Akkooi, A.C.J.; van den Braber, M.; Rozeman, E.A.; Haanen, J.; Blank, C.U.; et al. Dysfunctional CDB T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma. *Cell* 2019, 176, 775–789.e718. [CrossRef]
104. Zhang, L.; Yu, X.; Zheng, L.; Zhang, Y.; Li, Y.; Fang, Q.; Gao, R.; Kang, B.; Zhang, Q.; Huang, J.Y.; et al. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. *Nature* 2018, 564, 268–272. [CrossRef]

105. Goldstein, L.D.; Chen, Y.J.; Wu, J.; Chaudhuri, S.; Hsiao, Y.C.; Schneider, K.; Hoi, K.H.; Lin, Z.; Guerrero, S.; Jaiswal, B.S.; et al. Massively parallel single-cell B-cell receptor sequencing enables rapid discovery of diverse antigen-reactive antibodies. *Commun. Biol.* 2019, 2, 304. [CrossRef] [PubMed]

106. Li, F.; Luo, M.; Zhou, W.; Li, J.; Jin, X.; Xu, Z.; Juan, L.; Zhang, Z.; Li, Y.; Liu, R.; et al. Single cell RNA and immune repertoire profiling of COVID-19 patients reveal novel neutralizing antibody. *Protein Cell* 2020. [CrossRef] [PubMed]

107. Browaeys, R.; Saelens, W.; Saeyns, Y. NicheNet: Modeling intercellular communication by linking ligands to target genes. *Nat. Methods* 2020, 17, 159–162. [CrossRef] [PubMed]

108. Efremova, M.; Vento-Tormo, M.; Teichmann, S.A.; Vento-Tormo, R. CellPhoneDB: Inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes. *Nat. Protoc.* 2020, 15, 1484–1506. [CrossRef] [PubMed]